This section contains the latest highlighted research for patients from ASCO medical journals, including the Journal of Clinical Oncology, as well as an archive of research highlights from previous ASCO scientific meetings (2011-2015). For the latest research highlights from more recent ASCO meetings, visit the Cancer.Net Blog or check out Cancer.Net’s audio podcasts and videos for patients.
To search this archive, use the drop-down menu below. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
In a recent study, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent ovarian cancer from worsening for almost nine months longer than treatment with olaparib alone.
A large, long-term study showed for the first time that women with BRCA1 mutations should undergo preventive surgical removal of the ovaries (prophylactic oophorectomy) by age 35 to achieve the greatest reduction in ovarian cancer risk. Researchers showed that waiting until a later age to have the surgery was associated with a significantly higher ovarian cancer risk. In addition, the investigators reported for the first time that prophylactic oophorectomy reduces the overall risk of death by 77 percent among women with either a BRCA1 or BRCA2 mutation.
Women with advanced ovarian cancer or a related gynecologic cancer who receive treatment with the targeted therapy pazopanib (Votrient) following successful chemotherapy lived longer without their disease coming back than those receiving a placebo (an inactive treatment, often called a “sugar pill”), according to the results of a recent clinical trial. Pazopanib is medication taken by mouth that focuses on stopping angiogenesis, which is the process of making new blood vessels. Because a tumor needs the nutrients delivered by blood vessels to grow and spread, the goal of anti-angiogenesis therapy is to starve the tumor.
According to a recent study, giving bevacizumab (Avastin) along with standard chemotherapy doubled the time it took for platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers to worsen. These are all cancers of a woman's reproductive system that are treated similarly. Platinum-based chemotherapy is often the first treatment for these cancers and includes the drugs cisplatin (Platinol), carboplatin (Paraplat, Paraplatin), and oxaliplatin (Eloxatin). When platinum-based drugs stop working to control the cancer's growth, it is called platinum-resistant cancer.
An analysis of more than 3,000 families including women with breast cancer has found that close relatives of women who carry mutations in a BRCA gene - but who themselves do not have such genetic mutations - do not have an increased risk of developing breast cancer compared to relatives of women with breast cancer who do not have such mutations.
In two recent studies, researchers looked at the drug bevacizumab (Avastin) to treat recurrent and newly-diagnosed ovarian cancer. Bevacizumab is a type of targeted therapy, a treatment that targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.
A large study evaluating ovarian cancer screening showed that using both a CA-125 blood test and transvaginal ultrasound to find early ovarian cancer did not reduce the risk of dying from the disease and resulted in unnecessary follow-up procedures. The CA-125 blood test measures the amount of a tumor marker called CA-125, which may be found in higher levels in women with ovarian cancer. A transvaginal ultrasound uses sound waves to create pictures of the ovaries. Both tests are used to evaluate the symptoms of ovarian cancer, its stage, and the effectiveness of treatment.
In a recent study, the drug cabozantinib helped manage various advanced cancers, particularly prostate, ovarian, and liver cancers. The drug also helped shrink bone metastases (cancer that has spread to the bone). Cabozantinib is a type of targeted therapy, which means it targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.
In a recent study, researchers found that maintenance therapy with olaparib, a type of drug called a PARP inhibitor, increased the amount of time it took for recurrent ovarian cancer (cancer that has come back after treatment) to worsen. Maintenance therapy is ongoing treatment that is given after the standard treatment to help control the growth of cancer.